Analysts Remain Optimistic About Anavex Life Sciences Corp.’s Stock Despite a 1.78% Drop in Price in 2023.

March 18, 2023

Trending News ☀️

Analysts remain optimistic about Anavex Life Sciences ($NASDAQ:AVXL) Corp.’s stock despite a 1.78% drop in price in 2023. The company’s stock ended the day at $9.36, a decrease from its previous closing price of $9.53. Several analysts have even raised their outlook for the stock, citing the company’s recent successes in developing and testing new drugs as well as its continued commitment to research and development. Analysts point out that the one-day drop in price does not reflect the long-term prospects of the company. They suggest that Anavex Life Sciences Corp.’s stock still has potential for growth as the company continues to pursue new drug treatments and research initiatives.

The company has had several successful trials of new drugs over the past year and is expected to launch several more soon. Analysts are expecting these new drugs to be well-received, which could lead to an increase in stock price. The company’s dedication to research and its recent successes are seen as signs of a bright future for the company.

Price History

This news has been met with mostly positive coverage in the media, as the company still enjoys a lot of confidence in the industry. On Friday, ANAVEX LIFE SCIENCES stock opened at $9.4 and closed at $9.5, down by 0.3% from last closing price of 9.5. Despite the small drop, analysts are still very confident that the company will continue to perform well in the future. They continue to maintain a positive outlook on the stock and remain confident in their predictions that it will continue to perform well in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for AVXL. More…

    Total Revenues Net Income Net Margin
    0 -50.07
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for AVXL. More…

    Operations Investing Financing
    -26.53 0 19.01
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for AVXL. More…

    Total Assets Total Liabilities Book Value Per Share
    148.37 13.25 1.73
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for AVXL are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -24.6% -23.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale conducted an analysis of ANAVEX LIFE SCIENCES’ financials and the results indicate that ANAVEX LIFE SCIENCES is strong in terms of asset and weak in terms of dividend, growth, and profitability. It has been classified as an ‘elephant’, which is a company that is rich in assets after deducting off liabilities. Investors who are looking to invest in ANAVEX LIFE SCIENCES will likely be attracted by its strong asset base and intermediate health score of 4/10 with regard to its cashflows and debt. This suggests that it is likely to sustain future operations in times of crisis. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The Company’s lead drug candidate, ANAVEX 2-73, is being developed to treat Alzheimer’s disease (AD) and other CNS diseases. ANAVEX 2-73 is a small molecule that restores brain cell function and reverses the course of AD. The Company is also developing ANAVEX 3-71, which is in preclinical stage for the treatment of Parkinson’s disease and other CNS diseases. Both ANAVEX 2-73 and ANAVEX 3-71 target sigma-1 and muscarinic receptors.

    – AN2 Therapeutics Inc ($NASDAQ:ANTX)

    Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of December 31, 2020, the company had one marketed product, Jakafi (ruxolitinib), and two clinical-stage candidates in various stages of development. Jakafi is approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, and patients with relapsed or refractory acute myeloid leukemia (AML).

    – Aadi Bioscience Inc ($NASDAQ:AADI)

    Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic antibodies for the treatment of cancer and other serious diseases. The company has a market cap of 262.08M as of 2022 and a Return on Equity of -72.24%. Aadi Bioscience Inc’s products are in various stages of development, with the most advanced product candidate, AB101, being evaluated in a Phase 1/2 clinical trial in patients with relapsed or refractory B-cell malignancies.


    Anavex Life Sciences Corp. has been the subject of positive analyst sentiment despite its 1.78% drop in price in 2023. At the time of writing, news coverage surrounding the company is mostly positive, with analysts expecting the stock to perform well. Analysts have also pointed to the company’s promising portfolio of drug therapies currently in development, which are aimed at treating a variety of neurological disorders, as a reason for their optimism. Additionally, the company has a strong balance sheet and low debt levels, making it an attractive investment for those looking for long-term gains.

    Recent Posts

    Leave a Comment